Date: 2014-09-10
Type of information: Financing round
Company: Alize Pharma (France)
Investors: Bpifrance (France), Octalfa (France), Sham Innovation Sante (France), CEMA (Canada), TAB Consulting (France)
Amount: € 5 million
Funding type: financing round
Planned used: The funds will be used to continue the clinical program for AZP531, including the set-up and completion of two clinical trials: a Phase II trial in hyperphagia associated with Prader-Willi syndrome and a Phase Ib trial in type 2 diabetes. AZP531 is a stabilized analog of unacylated ghrelin, a gastro-intestinal hormone. It is under development by Alize Pharma SAS for use in various metabolic and cardiovascular indications. Two new clinical trials are expected to be launched in the last quarter of 2014. The aim is to provide preliminary data on the efficacy of AZP531 in two indications: hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder, and type 2 diabetes, a metabolic disease accounting for 90 per cent of the world’s diabetics (WHO, 2013). The trials follow on from two Phase I clinical trials carried out in healthy volunteers over the last 12 months.
Others: * On September 10, 2014, Alize Pharma SAS, an Alize Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announced that it has closed a new financing round of € 5 million ($ 6.6 million). The French public investment bank Bpifrance led the operation via the InnoBio fund. The InnoBio fund has taken an equity stake in the company with an investment of € 3.5 million ($ 4.6 million). Alize Pharma SAS’ historical investors: Octalfa, Sham Innovation Sante, CEMA and Tab Consulting have also contributed. Olivier Martinez and Mounia Chaoui (on behalf of Bpifrance and Sham Innovation Sante) will join the board of directors at Alize Pharma SAS. Its other members are Gilles Alberici from Octalfa, Andre de Villers from CEMA and Thierry Abribat from TAB Consulting.Since its creation in 2007, Alize Pharma SAS has raised a total of € 10 million ($ 13.2 million).
Therapeutic area: Metabolic diseases - Rare diseases
